BioTime (BTIM.PK)'s Subsidiary Embryome Sciences, Inc. Enters Agreement Adding New Embryonic Stem Cell Lines to Its Product Portfolio
2/27/2009 8:39:14 AM
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc., (OTCBB:BTIM) announced today that its wholly-owned subsidiary Embryome Sciences, Inc. has entered into an agreement with Reproductive Genetics Institute (RGI) of Chicago, Illinois granting Embryome Sciences rights to market new human embryonic stem cell (hES) lines selected by Embryome Sciences from 294 hES lines derived by RGI. Embryome Sciences will initially select 10 RGI hES cell lines, and may add additional cell lines at its option. RGI is a leading fertility center that screens embryos for genetic disorders, such as cystic fibrosis and muscular dystrophy prior to implantation. The RGI hES lines include both normal cells and 88 cell lines identified as carrying a host of inherited genetic disease genes that Embryome Sciences plans to sell as research products to universities and pharmaceutical companies.
comments powered by